AmplifyBio

AmplifyBio

AmplifyBio partners with clients to provide a single study or full IND enabling programs. AmplifyBio enhanced the core toxicology, safety, and efficacy capabilities offered with the addition of genetic and immune-modified animal models, dose routes, and surgical techniques to meet the needs of drug development clients. AmplifyBio has also invested significantly in bioanalytic capabilities for molecular and immunological assessments that complement in vivo work. The new labs include digital PCR platforms, spectral cytometry, in-vivo imaging, and improved immunological assay multiplexing ability to give a complete system picture of the drug’s function and characteristics at the preclinical stage. AmplifyBio partners with clients to provide preclinical CRO services including toxicology, safety, efficacy, and characterization studies and is further creating a novel development environment for the commercialization of both traditional small molecule drugs, and advanced therapies like CGTs.

Bioanalytical Services, CRO—Contract Research Organization, Genotoxicity Products/Services, In Vivo Research/Testing, Inhalation Research/Testing, Pathology, Pharmaceutical Product Safety/Toxicology, Pharmacology, Preclinical Research/Testing